Intraspinal cord delivery of IGF-I mediated by adeno-associated virus 2 is neuroprotective in a rat model of familial ALS.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Neurobiology of Disease

• Publication date

  2009-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.nbd.2008.12.003PMID 19135533
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• SUBCUTANEOUS IGF-1 IS NOT BENEFICIAL IN 2-YEAR ALS TRIAL

  2009cited by this paper
• Transgenics, toxicity and therapeutics in rodent models of mutant SOD1-mediated familial ALS.

  2008cited by this paper
• Subcutaneous IGF-1 is not beneficial in 2-year ALS trial

  2008cited by this paper
• Retrograde axonal transport and motor neuron disease

  2008cited by this paper
• Focal Transplantation-based Astrocyte Replacement is Neuroprotective in a Model of Motor Neuron Disease

  2008cited by this paper
• Efficient retrograde neuronal transduction utilizing self-complementary AAV1.

  2008cited by this paper
• Delivery of AAV-IGF-1 to the CNS extends survival in ALS mice through modification of aberrant glial cell activity.

  2008cited by this paper
• GDNF Secreting Human Neural Progenitor Cells Protect Dying Motor Neurons, but Not Their Projection to Muscle, in a Rat Model of Familial ALS

  2007cited by this paper
• Sexual dimorphism in disease onset and progression of a rat model of ALS

  2007cited by this paper
• Intraparenchymal spinal cord delivery of adeno-associated virus IGF-1 is protective in the SOD1G93A model of ALS.

  2007cited by this paper
• Adeno-associated viral-mediated insulin-like growth factor delivery protects motor neurons in vitro

  2007cited by this paper
• Comparative Analysis of Adeno-Associated Viral Vector Serotypes 1, 2, 5, 7, And 8 in Mouse Brain

  2007cited by this paper
• Targeted Spinal Cord Therapeutics Delivery: Stabilized Platform and Microelectrode Recording Guidance Validation

  2007cited by this paper
• Axonal transport and neurodegenerative disease.

  2006cited by this paper
• Gene‐based treatment of motor neuron diseases

  2006cited by this paper
• Background and gender effects on survival in the TgN(SOD1-G93A)1Gur mouse model of ALS.

  2005cited by this paper
• Adenoviral clostridial light chain gene-based synaptic inhibition through neuronal synaptobrevin elimination

  2005cited by this paper
• Synergy of insulin‐like growth factor‐1 and exercise in amyotrophic lateral sclerosis

  2005cited by this paper
• Therapeutic benefit of intrathecal injection of insulin-like growth factor-1 in a mouse model of Amyotrophic Lateral Sclerosis.

  2005cited by this paper
• Trophic activity of Rabies G protein-pseudotyped equine infectious anemia viral vector mediated IGF-I motor neuron gene transfer in vitro.

  2005cited by this paper
• Muscle expression of a local Igf-1 isoform protects motor neurons in an ALS mouse model

  2005cited by this paper
• Adeno-Associated Virus (AAV) Vectors in the CNS.

  2005cited by this paper
• Adeno-associated virus (AAV) vectors in the CNS.

  2005cited by this paper
• Gene therapy for ALS delivers.

  2004cited by this paper
• Clinical trials in neurological disorders using AAV vectors: promises and challenges.

  2004influential reference
• Cervical spinal cord delivery of a rabies G protein pseudotyped lentiviral vector in the SOD-1 transgenic mouse. Invited submission from the Joint Section Meeting on Disorders of the Spine and Peripheral Nerves, March 2004.

  2004cited by this paper
• Intramuscular injection of AAV-GDNF results in sustained expression of transgenic GDNF, and its delivery to spinal motoneurons by retrograde transport.

  2003cited by this paper
• Sexual differences in onset of disease and response to exercise in a transgenic model of ALS.

  2003cited by this paper
• Retrograde Viral Delivery of IGF-1 Prolongs Survival in a Mouse ALS Model

  2003cited by this paper
• Co‐administration of IGF‐I and glycosaminoglycans greatly delays motor neurone disease and affects IGF‐I expression in the wobbler mouse: a long‐term study

  2002cited by this paper
• Focal loss of the glutamate transporter EAAT2 in a transgenic rat model of SOD1 mutant-mediated amyotrophic lateral sclerosis (ALS)

  2002cited by this paper
• Brain damage, sex hormones and recovery: a new role for progesterone and estrogen?

  2001cited by this paper
• Gender difference in insulin-like growth factor I response to growth hormone (GH) treatment in GH-deficient adults: role of sex hormone replacement.

  2000cited by this paper
• Recombinant adeno-associated virus type 2, 4, and 5 vectors: transduction of variant cell types and regions in the mammalian central nervous system.

  2000cited by this paper
• Effects of neurotrophic factors on motoneuron survival following axonal injury in newborn rats

  2000cited by this paper
• Incidence and prevalence of ALS in Ireland, 1995–1997

  1999cited by this paper
• Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human.

  1998cited by this paper
• Systemic administration of insulin‐like growth factor decreases motor neuron cell death and promotes muscle reinnervation

  1998cited by this paper
• A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis. European ALS/IGF-I Study Group.

  1998cited by this paper
• A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis

  1998cited by this paper
• Adeno-associated virus expression systems for gene transfer.

  1998cited by this paper
• Effect of recombinant human insulin-like growth factor-I on progression of ALS

  1997cited by this paper
• Effect of recombinant human insulin-like growth factor-I on progression of ALS. A placebo-controlled study. The North America ALS/IGF-I Study Group.

  1997cited by this paper
• Sustained expression of genes delivered directly into liver and muscle by lentiviral vectors

  1997cited by this paper
• Second-strand synthesis is a rate-limiting step for efficient transduction by recombinant adeno-associated virus vectors

  1996cited by this paper
• Transduction with recombinant adeno-associated virus for gene therapy is limited by leading-strand synthesis

  1996cited by this paper
• Differential and persistent expression patterns of CNS gene transfer by an adeno-associated virus (AAV) vector.

  1996cited by this paper
• Natural history of amyotrophic lateral sclerosis in a database population. Validation of a scoring system and a model for survival prediction.

  1995cited by this paper
• Beneficial effects of insulin-like growth factor-I on wobbler mouse motoneuron disease.

  1995cited by this paper
• Estrogen action on hepatic synthesis of angiotensinogen and IGF-I: direct and indirect estrogen effects.

  1994cited by this paper
• Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain

  1994cited by this paper
• Neurotrophic agents prevent motoneuron death following sciatic nerve section in the neonatal mouse.

  1994cited by this paper
• The Potential of Insulin‐like Growth Factor‐I as a Therapeutic for the Treatment of Neuromuscular Disorders

  1993cited by this paper
• Insulin-like growth factors: putative muscle-derived trophic agents that promote motoneuron survival.

  1993cited by this paper
• Experimental rationale for the therapeutic use of neurotrophins in amyotrophic lateral sclerosis.

  1993cited by this paper
• Members of several gene families influence survival of rat motoneurons in vitro and in vivo

  1993cited by this paper
• Effects of astrocytes, insulin and insulin-like growth factor I on the survival of motoneurons in vitro.

  1992cited by this paper
• Risk factors in motor neuron disease: a case-control study.

  1991cited by this paper
• Localization of the phrenic nucleus in the spinal cord of man

  1956cited by this paper
• Localization of the phrenic nucleus in the spinal cord of man.

  1956cited by this paper
• Anatomy of the Rat

  1936cited by this paper

• Targeting Amyotrophic Lateral Sclerosis with Gene Therapy: From Silencing Genes to Enhancing Neuroprotection

  2025cites this paper
• Viral vectors in neurodegenerative diseases: immune responses and therapeutic applications

  2025cites this paper
• Applications and Developments of Gene Therapy Drug Delivery Systems for Neurological Disorders

  2024cites this paper
• ADENO-ASSOCIATED VIRUSES IN GENE THERAPY FOR SPINAL MUSCULAR ATROPHIES: TREND OR TRIUMPH?

  2023cites this paper
• Anti-apoptotic Splicing Variant of AIMP2 Recover Mutant SOD1-Induced Neuronal Cell Death

  2022cites this paper
• An Approach to Maximize Retrograde Transport Based on the Spatial Distribution of Motor Endplates in Mouse Hindlimb Muscles

  2021cites this paper
• Dysregulation of IGF-1/GLP-1 signaling in the progression of ALS: potential target activators and influences on neurological dysfunctions

  2021cites this paper
• Neurotrophic Therapy for ALS/MND

  2021cites this paper
• Focal and dose-dependent neuroprotection in ALS mice following AAV2-neurturin delivery.

  2020cites this paper
• Overcoming the blood-brain barrier in neurodegenerative disorders and brain tumours.

  2020cites this paper
• Insulin-like growth factor 1 signaling in motor neuron and polyglutamine diseases: From molecular pathogenesis to therapeutic perspectives.

  2020cites this paper
• Intracisternal IGF‐1 gene therapy abrogates kainic acid‐induced excitotoxic damage of the rat spinal cord

  2020cites this paper
• Targeted intraspinal injections to assess therapies in rodent models of neurological disorders

  2019cites this paper
• Therapeutic AAV Gene Transfer to the Nervous System: A Clinical Reality.

  2019cites this paper
• Gene Therapy for ALS—A Perspective

  2019cites this paper
• AAV gene delivery to the spinal cord: serotypes, methods, candidate diseases, and clinical trials

  2018cites this paper
• Modélisation et analyses physiopathologiques de la Sclérose Latérale Amyotrophique liée à l'ubiquiline 2 à l'aide de vecteurs AAV10

  2017cites this paper
• Gene Therapy for Amyotrophic Lateral Sclerosis

  2017cites this paper
• Multiple intracerebroventricular injections of human umbilical cord mesenchymal stem cells delay motor neurons loss but not disease progression of SOD1G93A mice.

  2017cites this paper
• Motor Neuron Gene Therapy: Lessons from Spinal Muscular Atrophy for Amyotrophic Lateral Sclerosis

  2017cites this paper
• Potential new complication in drug therapy development for amyotrophic lateral sclerosis

  2016cites this paper
• Trophic Factors in the Therapeutic Challenge Against ALS: Current Research Directions

  2016cites this paper
• Gene Therapy for the Treatment of Neurological Disorders: Amyotrophic Lateral Sclerosis.

  2016cites this paper
• The Paradoxical Signals of Two TrkC Receptor Isoforms Supports a Rationale for Novel Therapeutic Strategies in ALS

  2016cites this paper
• Adeno-Associated Virus-Based Gene Therapy for CNS Diseases

  2016cites this paper
• α CAR IGF‐1 vector targeting of motor neurons ameliorates disease progression in ALS mice

  2016cites this paper
• MicroNeurotrophins Improve Survival in Motor Neuron-Astrocyte Co-Cultures but Do Not Improve Disease Phenotypes in a Mutant SOD1 Mouse Model of Amyotrophic Lateral Sclerosis

  2016cites this paper
• Brain-Derived Neurotrophic Factor Facilitates Functional Recovery from ALS-Cerebral Spinal Fluid-Induced Neurodegenerative Changes in the NSC-34 Motor Neuron Cell Line

  2016cites this paper
• β2-Adrenoceptor agonists as novel, safe and potentially effective therapies for Amyotrophic lateral sclerosis (ALS).

  2016cites this paper
• Pharmacology of manipulating lean body mass

  2015cites this paper
• Autocrine Production of IGF‐I Increases Stem Cell‐Mediated Neuroprotection

  2015cites this paper
• Current developments in gene therapy for amyotrophic lateral sclerosis

  2015influential citation
• Histological Bulbar Manifestations in the ALS Rat

  2015cites this paper
• IGF-1/IGF-R Signaling in Traumatic Brain Injury: Impact on Cell Survival, Neurogenesis, and Behavioral Outcome

  2015cites this paper
• Histological Bulbar Manifestations in the ALS Rat

  2015cites this paper
• Antioxidant gene therapy against neuronal cell death.

  2014cites this paper
• Translating biological findings into new treatment strategies for amyotrophic lateral sclerosis (ALS).

  2014cites this paper
• Trophic Factor Production by Glial Cells in the Treatment of Amyotrophic Lateral Sclerosis

  2014cites this paper
• Polyethylene glycol-coupled IGF1 delays motor function defects in a mouse model of spinal muscular atrophy with respiratory distress type 1.

  2014cites this paper
• La trepanación vertebral como un método alternativo para la inoculación intraparenquimatosa de diversas suspensiones dentro de la médula espinal Vertebral Trepanation as an Alternative Method for Intraparenchymal Delivery of Suspensions into the Spinal Cord

  2014cites this paper
• Application of Viral Vectors to Motor Neuron Disorders

  2014cites this paper
• Progress in gene therapy for neurological

  2013cites this paper
• Progress in gene therapy for neurological disorders

  2013cites this paper
• Recent Advances in ALS Research: Perspectives for Personalized Clinical Application

  2013cites this paper
• Gene Therapy for Amyotrophic Lateral Sclerosis

  2013cites this paper
• Growth hormone secretion is correlated with neuromuscular innervation rather than motor neuron number in early-symptomatic male amyotrophic lateral sclerosis mice.

  2013cites this paper
• Role of Gigaxonin in the Regulation of Intermediate Filaments: a Study Using Giant Axonal Neuropathy Patient-Derived Induced Pluripotent Stem Cell-Motor Neurons

  2013cites this paper
• Rodent models of amyotrophic lateral sclerosis.

  2013cites this paper
• Genetic Modification of Adeno-Associated Virus Capsid for Enhanced Motor Neuron Delivery and Retrograde Transport

  2012cites this paper
• Research advances in gene therapy approaches for the treatment of amyotrophic lateral sclerosis

  2012cites this paper
• Potential for promoting recurrent laryngeal nerve regeneration by remote delivery of viral gene therapy

  2012cites this paper
• Cellular and molecular approaches to motor neuron therapy in amyotrophic lateral sclerosis and spinal muscular atrophy.

  2012cites this paper
• Stem cell therapy for the spinal cord

  2012cites this paper
• Amyotrophic lateral sclerosis: new insights into underlying molecular mechanisms and opportunities for therapeutic intervention.

  2012cites this paper
• Gene therapy for amyotrophic lateral sclerosis.

  2012cites this paper
• Insulin-like growth factors in the peripheral nervous system.

  2012cites this paper
• Dihydrotestosterone Ameliorates Degeneration in Muscle, Axons and Motoneurons and Improves Motor Function in Amyotrophic Lateral Sclerosis Model Mice

  2012cites this paper
• Ablation of Proliferating Cells in the CNS Exacerbates Motor Neuron Disease Caused by Mutant Superoxide Dismutase

  2012cites this paper
• Development of novel interventions to enhance muscle function

  2012cites this paper
• Robust spinal motor neuron transduction following intrathecal delivery of AAV9 in pigs

  2011cites this paper
• Therapeutic effects of PEGylated insulin-like growth factor I in the pmn mouse model of motoneuron disease.

  2011cites this paper
• Restorative effect of intracerebroventricular insulin-like growth factor-I gene therapy on motor performance in aging rats.

  2011cites this paper
• Genetic strategies to study TDP‐43 in rodents and to develop preclinical therapeutics for amyotrophic lateral sclerosis

  2011cites this paper
• Neuroprotection by gene therapy targeting mutant SOD1 in individual pools of motor neurons does not translate into therapeutic benefit in fALS mice.

  2011cites this paper
• Gene Therapy for Motor Neuron Disease

  2011cites this paper
• Can vitamin D delay the progression of ALS?

  2011cites this paper
• Development of lentiviral vectors targeted to P38MAPK inhibition and Akt activation in motor neurons of a mouse model of familial amyotrophic lateral sclerosis

  2010cites this paper
• Human adipose-derived stem cells enhance the glutamate uptake function of GLT1 in SOD1(G93A)-bearing astrocytes.

  2010cites this paper
• Thérapie génique pour les maladies neurodégénératives

  2010cites this paper
• Viral vectors and delivery strategies for CNS gene therapy.

  2010cites this paper
• Neurotrophic Growth Factors for the Treatment of Amyotrophic Lateral Sclerosis: Where Do We Stand?

  2010influential citation
• Viral vectors for neurotrophic factor delivery: a gene therapy approach for neurodegenerative diseases of the CNS.

  2010cites this paper
• Recent advances in amyotrophic lateral sclerosis research: perspectives for personalized clinical application

  2010cites this paper
• Review: Neuromuscular synaptic vulnerability in motor neurone disease: amyotrophic lateral sclerosis and spinal muscular atrophy

  2010cites this paper
• Insulin is a Two-Edged Knife on the Brain

  2009cites this paper
• Macrophage colony stimulating factor (M-CSF) exacerbates ALS disease in a mouse model through altered responses of microglia expressing mutant superoxide dismutase.

  2009cites this paper
• IGF-1:tetanus toxin fragment C fusion protein improves delivery of IGF-1 to spinal cord but fails to prolong survival of ALS mice.

  2009cites this paper
• A Conditioning Lesion Provides Selective Protection in a Rat Model of Amyotrophic Lateral Sclerosis

  2009cites this paper
• Send Orders of Reprints at Reprints@benthamscience.org Interactions of Growth Hormone, Insulin-like Growth Factor-1, and Ghrelin with the Blood-brain Barrier 2. Pharmacokinetics of the Simple Diffusion of Gh across the Bbb

  year unknowncites this paper
• Review In search for a gold-standard procedure to count motor neurons in the spinal cord

  year unknowncites this paper